Carcinoma of the Exocrine Pancreas
Histopathology Reporting Guide

<table>
<thead>
<tr>
<th>Family/Last name</th>
<th>Date of birth</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DD – MM – YYYY</td>
</tr>
<tr>
<td>Given name(s)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patient identifiers</th>
<th>Date of request</th>
<th>Accession/Laboratory number</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DD – MM – YYYY</td>
<td></td>
</tr>
</tbody>
</table>

Elements in black text are CORE. Elements in grey text are NON-CORE.

☑ indicates multi-select values ☐ indicates single select values

**SCOPE OF THIS DATASET** indicates multi-select values

☐ Information not provided
☐ Not administered
☐ Administered (select all that apply)

☐ Chemotherapy
☐ Radiotherapy
☐ Other, specify

**NEOADJUVANT THERAPY**

**OPERATIVE PROCEDURE** (select all that apply)

☐ Whipple pancreatectoduodenectomy
☐ Pylorus-preserving pancreatectoduodenectomy
☐ Distal pancreatectomy
☐ Total pancreatectomy
☐ Subtotal pancreatectomy

☐ Pancreatic resection (tick one of the options above) extended with one or more of the following additionally resected organs/structures:

☐ Vein
☐ Superior mesenteric vein
☐ Portal vein

☐ Artery(s)
☐ Superior mesenteric artery
☐ Common hepatic artery
☐ Coeliac trunk

☐ Other, specify

☐ Other, specify

**TUMOUR SITE** (select all that apply)

☐ No macroscopically visible tumour
☐ Pancreatic head
☐ Pancreatic body
☐ Pancreatic tail
☐ Other, specify

**TUMOUR DIMENSIONS**

Maximum tumour dimension (largest tumour)

| mm |

Additional dimensions (largest tumour)

| mm x mm |

Dimensions of additional smaller tumour foci

| mm x mm x mm |

Method of measurement (in case of neoadjuvant treatment)

☐ Approach 1 (largest overall dimensions)
☐ Approach 2 (summation of dimensions of each tumour focus)

*See Note for an explanation of the approaches to the method of measurement following neoadjuvant treatment.*

**TUMOUR FOCALITY**

☐ Unifocal

☐ Multifocal, specify number of tumours in specimen

☐ Cannot be assessed, specify

---

<table>
<thead>
<tr>
<th>HISTOLOGICAL TUMOUR TYPE</th>
<th>HISTOLOGICAL TUMOUR GRADE</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Value list from the World Health Organization Classification of Tumours of the Gastrointestinal Tract (2019))</td>
<td>(Not applicable)</td>
</tr>
<tr>
<td>Ductal adenocarcinoma</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Ductal adenocarcinoma not otherwise specified (NOS)</td>
<td>Grade X: Cannot be assessed</td>
</tr>
<tr>
<td>Adenosquamous carcinoma</td>
<td>Grade 1: Well differentiated</td>
</tr>
<tr>
<td>Colloid carcinoma</td>
<td>Grade 2: Moderately differentiated</td>
</tr>
<tr>
<td>Signet-ring cell (poorly cohesive cell) carcinoma</td>
<td>Grade 3: Poorly differentiated or undifferentiated</td>
</tr>
<tr>
<td>Medullary carcinoma NOS</td>
<td></td>
</tr>
<tr>
<td>Hepatoid carcinoma</td>
<td></td>
</tr>
<tr>
<td>Invasive micropapillary carcinoma</td>
<td></td>
</tr>
<tr>
<td>Large cell carcinoma with rhabdoid phenotype</td>
<td></td>
</tr>
<tr>
<td>Carcinoma, undifferentiated, NOS</td>
<td></td>
</tr>
<tr>
<td>Undifferentiated carcinoma with osteoclast-like giant cells</td>
<td></td>
</tr>
<tr>
<td>Acinar cell carcinoma</td>
<td></td>
</tr>
<tr>
<td>Acinar cell cystadenocarcinoma</td>
<td></td>
</tr>
<tr>
<td>Mixed acinar-neuroendocrine carcinoma</td>
<td></td>
</tr>
<tr>
<td>Mixed acinar-endocrine-ductal carcinoma</td>
<td></td>
</tr>
<tr>
<td>Mixed acinar-ductal carcinoma</td>
<td></td>
</tr>
<tr>
<td>Acinar cell carcinoma, NOS</td>
<td></td>
</tr>
<tr>
<td>Intraductal papillary mucinous neoplasm with associated invasive carcinoma</td>
<td></td>
</tr>
<tr>
<td>Intraductal oncocytic papillary neoplasm with associated invasive carcinoma</td>
<td></td>
</tr>
<tr>
<td>Intraductal tubulopapillary neoplasm with associated invasive carcinoma</td>
<td></td>
</tr>
<tr>
<td>Mucinous cystic neoplasm with associated invasive carcinoma</td>
<td></td>
</tr>
<tr>
<td>Other, specify</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EXTENT OF INVASION (select all that apply)</th>
<th>LYMPHATIC AND VENOUS INVASION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cannot be assessed</td>
<td>Not identified</td>
</tr>
<tr>
<td>No evidence of primary tumour</td>
<td>Present</td>
</tr>
<tr>
<td>Tumour is confined to pancreas</td>
<td>Lymphatic invasion</td>
</tr>
<tr>
<td>Invasion into ampulla of Vater</td>
<td>Venous invasion</td>
</tr>
<tr>
<td>Invasion into duodenum</td>
<td></td>
</tr>
<tr>
<td>Invasion into common bile duct</td>
<td></td>
</tr>
<tr>
<td>Invasion into peripancreatic soft tissues</td>
<td></td>
</tr>
<tr>
<td>Invasion into spleen</td>
<td></td>
</tr>
<tr>
<td>Invasion into splenic vein/artery</td>
<td></td>
</tr>
<tr>
<td>Invasion into vascular resection</td>
<td></td>
</tr>
<tr>
<td>Invasion into venous resection</td>
<td>Specify which vein</td>
</tr>
<tr>
<td>Specify maximum depth of invasion</td>
<td>Tunica adventitia</td>
</tr>
<tr>
<td></td>
<td>Tunica media</td>
</tr>
<tr>
<td></td>
<td>Tunica intima</td>
</tr>
<tr>
<td></td>
<td>Vascular lumen</td>
</tr>
<tr>
<td>Invasion into arterial resection</td>
<td>Specify which artery(s)</td>
</tr>
<tr>
<td>Specify maximum depth of invasion</td>
<td>Tunica adventitia</td>
</tr>
<tr>
<td></td>
<td>Tunica media</td>
</tr>
<tr>
<td></td>
<td>Tunica intima</td>
</tr>
<tr>
<td></td>
<td>Vascular lumen</td>
</tr>
<tr>
<td>Invasion into other adjacent structure(s)/organ(s), specify</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PERINEURAL INVASION</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Not identified</td>
<td></td>
</tr>
<tr>
<td>Present</td>
<td></td>
</tr>
<tr>
<td>Lymphatic invasion</td>
<td></td>
</tr>
<tr>
<td>Venous invasion</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

RESPONSE TO NEOADJUVANT THERAPY

- No neoadjuvant treatment
- Complete response – no viable cancer cells (score 0)
- Near complete response – single cells or rare groups of cancer cells (score 1)
- Partial response – residual cancer with evident tumour regression (score 2)
- Poor or no response – extensive residual cancer with no evident tumour regression (score 3)
- Cannot be assessed, specify

MARGIN STATUS

Pancreatic transection margin

- Not applicable
- Cannot be assessed
- Involved
  - Invasive carcinoma
  - High grade dysplasia
- Not involved
  - Distance of tumour from closest margin

Bile duct transection margin

- Not applicable
- Cannot be assessed
- Involved
- Not involved
  - Distance of tumour from closest margin

Gastric/proximal duodenal transection margin

- Not applicable
- Cannot be assessed
- Involved
- Not involved
  - Distance of tumour from closest margin

Posterior dissection margin

- Not applicable
- Cannot be assessed
- Involved
- Not involved
  - Distance of tumour from closest margin

Superior mesenteric artery (SMA) dissection margin

- Not applicable
- Cannot be assessed
- Involved
- Not involved
  - Distance of tumour from closest margin

Superior mesenteric vein (SMV) dissection margin

- Not applicable
- Cannot be assessed
- Involved
- Not involved
  - Distance of tumour from closest margin

Anterior pancreatic surface

- Not applicable
- Cannot be assessed
- Involved
- Not involved
  - Distance of tumour from closest margin

Transsection margins of venous resection

- Not applicable
- Cannot be assessed
- Involved
- Not involved
  - Distance of tumour from closest margin

Transsection margins of arterial resection

- Not applicable
- Cannot be assessed
- Involved
- Not involved
  - Distance of tumour from closest margin

Other margin(s), specify

- Not applicable
- Cannot be assessed
- Involved
- Not involved
  - Distance of tumour from closest margin

LYMPH NODE STATUS

- Cannot be assessed
- No nodes submitted or found
  - Number of lymph nodes examined
    - Not involved
    - Involved
    - Number of involved lymph nodes

ADDITIONAL FINDINGS (select all that apply)

- Chronic pancreatitis
- Pancreatic intraepithelial neoplasia, specify highest grade
- Intraductal papillary mucinous neoplasia, specify highest grade
- Neuroendocrine tumour, specify grade
- Other, specify
HISTOLOGICALLY CONFIRMED DISTANT METASTASES

- Not assessed
- Not identified
- Present, specify site(s)

ANCILLARY STUDIES

- Not performed
- Performed, specify

PATHOLOGICAL STAGING (UICC TNM 8\textsuperscript{th} edition)\textsuperscript{c}

**TNM Descriptors** (only if applicable) (select all that apply)

- m - multiple primary tumours
- r - recurrent
- y - post-therapy

**Primary tumour (pT)**

- TX Primary tumour cannot be assessed
- T0 No evidence of primary tumour
- Tis Carcinoma in situ\textsuperscript{d}
- T1 Tumour 2 cm or less in greatest dimension
  - T1a Tumour 0.5 cm or less in greatest dimension
  - T1b Tumour greater than 0.5 cm and no more than 1 cm in greatest dimension
  - T1c Tumour greater than 1 cm but no more than 2 cm in greatest dimension
- T2 Tumour more than 2 cm but no more than 4 cm in greatest dimension
- T3 Tumour more than 4 cm in greatest dimension
- T4 Tumour involves coeliac axis, superior mesenteric artery and/or common hepatic artery

\textsuperscript{d} Tis also includes the 'PanIN–III' classification.

**Regional lymph nodes (pN)**

- No nodes submitted or found
- NX Regional lymph nodes cannot be assessed
- N0 No regional lymph node metastasis
- N1 Metastases in 1 to 3 regional lymph nodes
- N2 Metastases in 4 or more regional lymph nodes

\textsuperscript{c} Reproduced with permission. Source: UICC TNM Classification of Malignant Tumours, 8\textsuperscript{th} Edition, eds by James D. Brierley, Mary K. Gospodarowicz, Christian Wittekind. 2016, Publisher Wiley-Blackwell.